Infinity Pharmaceuticals, Inc.
INFIQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 583.00K | 731.00K | 543.00K | 712.00K | 686.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 583.00K | 731.00K | 543.00K | 712.00K | 686.00K |
| Cost of Revenue | 6.95M | 6.29M | 7.29M | 8.09M | 9.21M |
| Gross Profit | -6.37M | -5.56M | -6.75M | -7.38M | -8.52M |
| SG&A Expenses | 3.75M | 5.94M | 2.79M | 3.50M | 3.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.70M | 12.24M | 10.08M | 11.59M | 12.70M |
| Operating Income | -10.12M | -11.51M | -9.54M | -10.88M | -12.02M |
| Income Before Tax | -9.96M | -11.05M | -9.23M | -10.72M | -11.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.96M | -11.05M | -9.23M | -10.72M | -11.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.96M | -11.05M | -9.23M | -10.72M | -11.99M |
| EBIT | -10.12M | -11.51M | -9.54M | -10.88M | -12.02M |
| EBITDA | -10.01M | -11.40M | -9.43M | -10.77M | -11.90M |
| EPS Basic | -0.11 | -0.12 | -0.10 | -0.12 | -0.13 |
| Normalized Basic EPS | -0.07 | -0.08 | -0.06 | -0.07 | -0.08 |
| EPS Diluted | -0.11 | -0.12 | -0.11 | -0.12 | -0.13 |
| Normalized Diluted EPS | -0.07 | -0.08 | -0.06 | -0.07 | -0.08 |
| Average Basic Shares Outstanding | 89.89M | 89.41M | 89.36M | 89.39M | 89.16M |
| Average Diluted Shares Outstanding | 89.89M | 89.41M | 89.36M | 89.39M | 89.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |